Blueprint Medicines Stock (NASDAQ: BPMC) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 0 / 792.978K |
Day Range | - - - |
52 Wk Range | 43.890 - 101.000 |
Market Cap | $5.556B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 52 |
Short Interest | 9.6% |
Days to Cover | 5.06 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Blueprint Medicines (NASDAQ: BPMC) through any online brokerage.
Other companies in Blueprint Medicines’s space includes: Immunovant (NASDAQ:IMVT), Legend Biotech (NASDAQ:LEGN), Ultragenyx Pharmaceutical (NASDAQ:RARE), Exact Sciences (NASDAQ:EXAS) and Ionis Pharmaceuticals (NASDAQ:IONS).
The latest price target for Blueprint Medicines (NASDAQ: BPMC) was reported by JMP Securities on Wednesday, April 10, 2024. The analyst firm set a price target for 114.00 expecting BPMC to rise to within 12 months (a possible 25.65% upside). 36 analyst firms have reported ratings in the last year.
The stock price for Blueprint Medicines (NASDAQ: BPMC) is $90.73 last updated April 25, 2024 at 4:20 PM EDT.
There are no upcoming dividends for Blueprint Medicines.
Blueprint Medicines’s Q1 earnings are confirmed for Thursday, May 2, 2024.
There is no upcoming split for Blueprint Medicines.
Blueprint Medicines is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.